Fig. 6: Liver Psd3 downregulation in mice fed a NASH-inducing diet reduced the severity of steatosis, inflammation and NAS, and liver collagen levels.
From: PSD3 downregulation confers protection against fatty liver disease
C57BL/6 male mice were fed a NASH-inducing diet for a total of 50 weeks and during the last 16 weeks, groups of mice were dosed via once weekly subcutaneous injections with saline (n = 10 animals), control GalNAc–ASO (n = 9 animals, 5 mg per kg body weight per week) or Psd3 GalNAc–ASO (n = 10 animals, 5 mg per kg body weight per week). a–d, Psd3 GalNAc–ASO reduced liver Psd3 mRNA expression levels (a) and was associated with reduced liver weight (b), total liver triglyceride content (c) and plasma ALT levels (d). e,f, Psd3 GalNAc–ASO treatment reduced liver Col1a1 protein levels (e) and liver lipid droplet number (f). g–j, Psd3 GalNAc–ASO treatment reduced the severity of steatosis (g), inflammation (h) and NAS (i), although there were no significant changes in liver fibrosis grade (j). a–f, Data are presented as mean ± s.d. Two-sided P values were calculated by one-way ANOVA Kruskal–Wallis non-parametric test followed by Dunn’s correction for multiple comparisons. Multiple comparisons were performed between the mean of each group and the mean of the control group (Ctr GalNAc–ASO). g–j, Data are presented as prevalence (%) of the specified disease’s degree. Colour shading from white to black indicates increased disease severity. Two-sided P values were calculated by using ordinal regression analyses. NS, non-significant.
